Journal article
Thermogenic effect of amrinone in healthy men.
- Ruttimann Y Department of Anesthesiology, University Hospital, Lausanne, Switzerland.
- Chioléro R
- Revelly JP
- Jeanprêtre N
- Schutz Y
- 1994-08-01
Published in:
- Critical care medicine. - 1994
Adult
Amrinone
Basal Metabolism
Body Temperature Regulation
Calorimetry, Indirect
Carbon Dioxide
Energy Metabolism
Hemodynamics
Humans
Infusions, Intravenous
Injections, Intravenous
Male
Oxygen Consumption
Prospective Studies
English
OBJECTIVES
The thermogenic effect of amrinone is unknown and its utilization in patients with severe cardiac failure could potentially increase oxygen requirements and therefore aggravate oxygen debt. Consequently, the present study was undertaken to assess the thermogenic response to amrinone at three different plasma concentrations under controlled conditions and to analyze amrinone's effects on various biochemical variables.
DESIGN
A prospective, unblinded, controlled study. The initial control period was followed by three sequential, experimental treatments.
SUBJECTS
Ten young, healthy, male volunteers with normal body weight.
INTERVENTIONS
Three experimental periods. Amrinone was administered intravenously in progressive doses: a) 0.5 mg/kg followed by 5 micrograms/kg/min; b) 0.5 mg/kg followed by 10 micrograms/kg/min; and c) 1.0 mg/kg followed by 10 micrograms/kg/min.
MEASUREMENTS AND MAIN RESULTS
Oxygen consumption (VO2) and CO2 production were continuously measured by means of a computerized indirect calorimeter. At the highest dose, amrinone produced a slight and significant (p < .01) increase in VO2 and in resting metabolic rate (+4.5% and +3.7%, respectively), while no change in CO2 production or in respiratory quotient occurred throughout the study. At the medium and high doses, amrinone increased plasma free fatty acid concentrations by 38% and 53%, respectively (p < .05). No variation in plasma glucose, lactate, insulin, norepinephrine, or epinephrine concentrations was observed during the study.
CONCLUSIONS
Amrinone administered intravenously at therapeutic doses has minimal thermogenic and metabolic effects in humans without cardiac failure.
The thermogenic effect of amrinone is unknown and its utilization in patients with severe cardiac failure could potentially increase oxygen requirements and therefore aggravate oxygen debt. Consequently, the present study was undertaken to assess the thermogenic response to amrinone at three different plasma concentrations under controlled conditions and to analyze amrinone's effects on various biochemical variables.
DESIGN
A prospective, unblinded, controlled study. The initial control period was followed by three sequential, experimental treatments.
SUBJECTS
Ten young, healthy, male volunteers with normal body weight.
INTERVENTIONS
Three experimental periods. Amrinone was administered intravenously in progressive doses: a) 0.5 mg/kg followed by 5 micrograms/kg/min; b) 0.5 mg/kg followed by 10 micrograms/kg/min; and c) 1.0 mg/kg followed by 10 micrograms/kg/min.
MEASUREMENTS AND MAIN RESULTS
Oxygen consumption (VO2) and CO2 production were continuously measured by means of a computerized indirect calorimeter. At the highest dose, amrinone produced a slight and significant (p < .01) increase in VO2 and in resting metabolic rate (+4.5% and +3.7%, respectively), while no change in CO2 production or in respiratory quotient occurred throughout the study. At the medium and high doses, amrinone increased plasma free fatty acid concentrations by 38% and 53%, respectively (p < .05). No variation in plasma glucose, lactate, insulin, norepinephrine, or epinephrine concentrations was observed during the study.
CONCLUSIONS
Amrinone administered intravenously at therapeutic doses has minimal thermogenic and metabolic effects in humans without cardiac failure.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1097/00003246-199408000-00006
- PMID 8045142
- Persistent URL
- https://sonar.ch/global/documents/264274
Export to…
Statistics
Document views: 45
File downloads: